Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing

By LabMedica International staff writers
Posted on 09 Sep 2026
Fluoropyrimidine-based chemotherapy can lead to severe toxicity in patients with specific variants in the dihydropyrimidine dehydrogenase (DPYD) gene, making pre-treatment assessment a critical step in oncology care. More...
Pharmacogenetic testing enables clinicians to make more informed chemotherapy decisions and optimize patient management in routine practice.
 
Yourgene Health (Manchester, UK) has introduced the IVDR-certified Yourgene Insight DPYD assay, with the commercial launch announced on September 8, 2026 in Paris and Manchester. The rollout follows the assay’s availability as a Research Use Only product in May 2026 and completes its transition to full compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR). The launch expands the company’s clinical genetics portfolio across regulated European markets.
 
The assay uses an ARMS (amplification refractory mutation system) allele‑specific amplification workflow designed for routine laboratory adoption. It includes ready‑to‑use reagents and streamlined data interpretation tools intended to expedite treatment decision‑making. The test was developed in close collaboration with leading clinicians and underwent extensive evaluation to ensure it meets everyday diagnostic needs.
 
The Yourgene Insight DPYD assay enables accurate detection of 19 clinically relevant DPYD variants to support identification of patients at increased risk of severe toxicity from fluoropyrimidine‑based therapy. It is positioned as the first CE‑marked, IVDR‑conforming DPYD test to incorporate all current Tier 1 and Tier 2 variants recommended by both the Association for Molecular Pathology (AMP) and the National Comprehensive Cancer Network (NCCN). By aligning content with these recommendations, the assay provides laboratories with a comprehensive solution to support informed chemotherapy dosing and patient management.
 
The company high that IVDR certification broadens market access for the product across highly regulated European settings and reflects continued growth of its clinically focused molecular diagnostics portfolio.
 
“The launch of the IVDR-certified Yourgene Insight DPYD assay is an important milestone for Novacyt and demonstrates our ability to translate scientific innovation into clinically relevant products that address urgent healthcare needs. As precision medicine continues to evolve, pharmacogenomic testing is becoming increasingly important in supporting safer and more effective treatment decisions,” said Lyn Rees, Chief Executive Officer of Novacyt.
 
“By delivering the first IVDR-certified DPYD assay incorporating all recommended Tier 1 and Tier 2 variants, we are providing laboratories with a comprehensive solution that aligns with the latest clinical guidance. This launch further strengthens our clinical genetics portfolio and supports our strategy of building a differentiated, high-value molecular diagnostics business,” added Rees.

Related Links
Yourgene Health

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.